These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 201375)

  • 41. Role of intracisternal A-particles and of RNA molecules in plasmacytoma-associated immunodeficiency.
    Katzmann J; Bhoopalam N; Heller P; Hwang LT; Ostro M; Lavelle D; Giacomoni D
    Cancer Res; 1978 Aug; 38(8):2555-61. PubMed ID: 307429
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. I. Methodological studies on the Winn assay.
    Wang KC; Berczi I; Sehon AH
    Int J Cancer; 1980 Apr; 25(4):487-92. PubMed ID: 7372372
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hybrid resistance to BALB/c plasmacytomas: F1 hybrid anti-MPC-11 immunological responses correlated with resistance to tumor challenge.
    Marsili MA; Walker MC; Phillips-Quagliata JM
    Cancer Res; 1986 Jan; 46(1):190-7. PubMed ID: 3484380
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Loss of oncogenicity and concomitant increased immunogenicity of murine plasmacytoma cell lines.
    Sorenson GD; Pettengill OS; Cate CC
    Am J Pathol; 1978 Mar; 90(3):565-82. PubMed ID: 629324
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibitory effect of endotoxin on the growth of plasma cell tumor.
    Bober LA; Kranepool MJ; Hollander VP
    Cancer Res; 1976 Mar; 36(3):927-9. PubMed ID: 766964
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new model of active specific immunotherapy using interleukin-1 and sonicated tumor supernatant in murine tumor system.
    Moriguchi Y; Kan N; Okino T; Harada T; Yamasaki S; Ichinose Y; Li L; Sugie T; Imamura M
    J Surg Oncol; 1996 Jun; 62(2):78-85. PubMed ID: 8649045
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor-specific humoral antibodies against plasma cell tumors in immunized BALB/c mice.
    Lespinats G
    J Natl Cancer Inst; 1970 Nov; 45(5):845-51. PubMed ID: 18605410
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy.
    Daley MJ; Gebel HM; Lynch RG
    J Immunol; 1978 May; 120(5):1620-4. PubMed ID: 77876
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis by immunoelectron microscopy of type-C viruses associated with primary and short-term transplanted mouse plasma cell tumors.
    Aoki T; Potter M; Sturm MM
    J Natl Cancer Inst; 1973 Nov; 51(5):1609-17. PubMed ID: 4357763
    [No Abstract]   [Full Text] [Related]  

  • 50. [Effect of the cell dose on the development of 2 transplantable tumors in a syngeneic host].
    Pugliese A; Choc O
    G Batteriol Virol Immunol; 1976; 69(1-6):122-31. PubMed ID: 15919
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Surface immunoglobulins of lymphocytes in mouse plasmacytoma. IV. Evidence for the persistence of the effect of plasmacytoma-RNA on the surface immunoglobulins of normal lymphocytes in vivo and in vitro.
    Bhoopalam N; Yakulis V; Giacomoni D; Heller P
    Clin Exp Immunol; 1976 Jan; 23(1):139-48. PubMed ID: 57019
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of an IgM plasmacytoma (TEPC-183) on the primary immune response of BALB/c mice.
    Havas HF; Schiffman G
    Immunology; 1978 Jan; 34(1):1-8. PubMed ID: 23993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.
    Barker E; Mokyr MB
    Cancer Immunol Immunother; 1987; 25(3):215-24. PubMed ID: 3677124
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Passive immunity to murine plasmacytoma by rabbit antiidiotypic antibody to myeloma protein.
    Chen Y; Yakulis V; Heller P
    Proc Soc Exp Biol Med; 1976 Jan; 151(1):121-5. PubMed ID: 1250837
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantitation of total-body tumor cells (MOPC 104E). I. Subcutaneous tumor model.
    Ghanta VK; Hiramoto RN
    J Natl Cancer Inst; 1974 Apr; 52(4):1199-202. PubMed ID: 4826588
    [No Abstract]   [Full Text] [Related]  

  • 56. C-type virus particles in urethan-induced pulmonary and renal carcinomas, in cell-graft-transmitted carcinosarcomas, and in filtrate-induced lymphomas in mice.
    Gross L; Feldman D; Dreyfuss Y; Ehrenreich T; Moore LA
    Cancer Res; 1976 Jan; 36(1):181-8. PubMed ID: 174806
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of dextran-S (alpha, 1-3 dextran) on the growth of plasmacytomas MOPC-104E and J558.
    Bhoopalam N; Heller P; Meyerstein N; Hall L
    J Immunol; 1980 Oct; 125(4):1454-8. PubMed ID: 6157734
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dissociation of depressed general immunocompetence and anti-tumor immunity in plasmacytoma-bearing mice demonstrating suppressor cell activity.
    Padarathsingh ML; Dean JH; Jerrells TR; Keys L; McCoy JL; Law LW
    Cell Mol Biol Incl Cyto Enzymol; 1980; 26(6):589-95. PubMed ID: 6452210
    [No Abstract]   [Full Text] [Related]  

  • 59. Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein.
    Freedman PM; Autry JR; Tokuda S; Williams RC
    J Natl Cancer Inst; 1976 Apr; 56(4):735-40. PubMed ID: 56452
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Suppression of the humoral immune response by particulate material extracted from spleen cell subpoulations of MOPC-315 tumor-bearing mice.
    Kleinman R
    Immunol Commun; 1979; 8(2):131-43. PubMed ID: 374242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.